Topics:

Two Orphan Drug Designations Granted for Reviroc in NHL

Two Orphan Drug Designations Granted for Reviroc in NHL

The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)—one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

 
Loading comments...
Please Wait 20 seconds or click here to close